Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.

Abstract

PURPOSE Radiation oncologists rely on available clinical information (biopsy Gleason score and prostate-specific antigen [PSA]) to determine the optimal treatment regimen for each prostate cancer patient. Existing published nomograms correlating clinical to pathologic extent of disease were based on patients treated in the 1980s and 1990s at select academic… (More)
DOI: 10.1016/j.ijrobp.2015.01.051

Topics

Cite this paper

@article{Caster2015RiskOP, title={Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.}, author={Joseph M. Caster and Aaron D. Falchook and Laura H Hendrix and Ronald C. Chen}, journal={International journal of radiation oncology, biology, physics}, year={2015}, volume={92 2}, pages={244-51} }